{
  "name": "SynAct Pharma AB",
  "slug": "synact-pharma-ab",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-07T08:04:20Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-06: stängning 19.14, volym 93796",
  "mfn_status": "resolved_no_reports",
  "mfn_count": 0,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/synact-pharma-ab/reports",
    "count": 16,
    "nasdaq_count": 16,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-05-27",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "SynAct Pharma publicerar delårsrapport Q1 2026",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4dbd3f271989f587de7c9243c1fc78e8&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aef628bb051762f152807cda4a5c133c9",
            "date": "2026-05-27",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "SynAct_Pharma_Q1_2026_Delarsrapport.pdf",
            "text_chars": 89833,
            "sha256": "2e857f4d02c1d3a9483800a2d9b775729fff9fed9ee497f0973f7e87322e4b97",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 89833
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-04-15",
        "title": "Årsredovisning 2025",
        "original_title": "SynAct Pharma publicerar årsredovisning för 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b6a5a1ede73128c3217fb82c7e1b9a1cf&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a459e70f487d42df785c6bb5c7faf489a",
            "date": "2026-04-15",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "SynAct_Pharma_AB_Arsredovisning_2025.pdf",
            "text_chars": 285170,
            "sha256": "990b1b3dd10a421ca68244074ce2aef48d441b54944c9d912f57803bcc3c6e91",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 179057
              },
              {
                "number": 2,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 106111
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-18",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "SynAct Pharma bokslutskommuniké för 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bc31286864fea797564f598cedd475419&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aacfe3c91766da9d853ef2d782fed5c73",
            "date": "2026-02-18",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "SynAct_Pharma_Q4_2025_Delarsrapport.pdf",
            "text_chars": 90669,
            "sha256": "2b486bd51ce23ff281f5af5b5a73213867292be738267531cfc10cf2bf1f5de1",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 90669
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-10-30",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "SynAct Pharma publicerar delårsrapport Q3 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b7b6fd4c4508279a30ae185e81bf1b6b5&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a9aa6754168c9d211bb79cf0bd9ea3c4e",
            "date": "2025-10-30",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "SynAct_Pharma_Q3_2025_Delarsrapport.pdf",
            "text_chars": 89961,
            "sha256": "334a266722ca6536cd1fa365a15bbb2bae489b22f558e145500792e705e29151",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 89961
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-20",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "SynAct Pharma publicerar delårsrapport Q2 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b90dc6f2e84323bd7f31e7974e18f0898&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/abb85308bea260d076ba2c5c4f3950960",
            "date": "2025-08-20",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "SynAct_Pharma_Q2_2025_Delarsrapport.pdf",
            "text_chars": 85186,
            "sha256": "89acc586725d0dc585547f14d032093321e136369e5576f1b9bdb89a7d394660",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 85186
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-05-27",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "SynAct Pharma publicerar delårsrapport Q1 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba8ac9ab3446edc51940e263080806c03&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/af03394fd18f44f9f7460b90bb573c281",
            "date": "2025-05-27",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "SynAct_Pharma_Q1_2025_Delarsrapport.pdf",
            "text_chars": 79745,
            "sha256": "f7fbf9bd26e12ccbb00005fd5f31a781c88390c9b399700675a1767f6b0fb6a2",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 79745
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-04-10",
        "title": "Årsredovisning 2024",
        "original_title": "SynAct Pharma publicerar årsredovisning för 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b1214e81951fde15c9da3d2bcf8be9b16&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a55291ac91810d4e6b483d2b5b3ff628e",
            "date": "2025-04-10",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "SynAct_Pharma_AB_Arsredovisning_2024.pdf",
            "text_chars": 280555,
            "sha256": "ce15cb2f11cde6b84bb7906187c0d60655e366a6916d188b4d0af5be1d3756ed",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 179972
              },
              {
                "number": 2,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 100581
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-18",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "SynAct Pharma bokslutskommuniké för 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bd249300c7365a92e6482feeacfdc0cab&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a7244d301ff63415f15fa946cdc137082",
            "date": "2025-02-18",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "SynAct_Pharma_Q4_2024_Delarsrapport.pdf",
            "text_chars": 77354,
            "sha256": "569b64ec4f7fc3bfe36417d573ad58a3909b9b3e69986e46c391cdd9eeb7a0fd",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 77354
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-10-30",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "SynAct Pharma publicerar delårsrapport Q3 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b97d88d92d29c13e7aa9b3d7bf24d8e25&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a624caea2485d1f24373c8eeaaa8a03be",
            "date": "2024-10-30",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "SynAct_Pharma_Q3_2024_Delarsrapport.pdf",
            "text_chars": 76160,
            "sha256": "7c8a711c3a4d3d8fa874537d61836642f5675e790a2499701709ecbc2640eba7",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 76160
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-08-20",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "SynAct Pharma publicerar delårsrapport Q2 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b1d9932af6f1a16016e700cfcd7b14f9e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a9661055a47fa9fd0ca97f5c3119534ca",
            "date": "2024-08-20",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "SynAct_Pharma_Q2_2024_Delarsrapport.pdf",
            "text_chars": 69351,
            "sha256": "fa27f4242fb3a44034232792f64bf5f3afb3870e46a9daf45c4abca310838a00",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 69351
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-05-31",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "SynAct Pharma publicerar delårsrapport Q1 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bddb5d73bca5448c9b63d6c335290d7db&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aaf75ad2e30ba61a9470d9cf567dd8be5",
            "date": "2024-05-31",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "SynAct_Pharma_Q1_2024_Delarsrapport.pdf",
            "text_chars": 68803,
            "sha256": "913da495e5a30426e81fae77abcf35d33ce3b31cb011c79aacef0a522670f8f2",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 68803
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-03-26",
        "title": "Årsredovisning 2023",
        "original_title": "SynAct Pharma publicerar årsredovisning för 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b65e28271844cd29144b0e0f323241a74&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a1ec65c58dae6cb556634909826df1f8f",
            "date": "2024-03-26",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "SynAct_Pharma_AB_Arsredovisning_2023.pdf",
            "text_chars": 293672,
            "sha256": "9b266db204f6a3f046d1e162c09a076f94e134618085bb805c9248e197fe3732",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 179635
              },
              {
                "number": 2,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 114035
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-02-23",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "SynAct Pharma AB (publ) (”SynAct”) publicerar idag delårsrapport för det fjärde kvartalet och helåret 2023.",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b01eef9f2d05259bf2fb87a11839d9a60&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a9cf323e4ab27f6b24e4e9b52cd7e85c4",
            "date": "2024-02-23",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "SynAct_Pharma_Q4_2023_Delarsrapport.pdf",
            "text_chars": 79563,
            "sha256": "2ab48236d6bcfe24afc35c6544ae3ec7a6b4d2926f084c562312dc86e60efd2c",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 79563
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-10-24",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "SynAct Pharma publicerar delårsrapport Q3 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b1daab32671cfe3955a09678f5a63dc50&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a2addd2988ae7f74674ece98ee7708eff",
            "date": "2023-10-24",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "SynAct_Pharma_Q3_2023_Delarsrapport.pdf",
            "text_chars": 81241,
            "sha256": "55926ab9c1a78796f8773eced3b263b36a0e3f208958fc49f33948407ae5e0f9",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 81241
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-08-04",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "SynAct Pharma publicerar delårsrapport Q2 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bbffe932055b30853e88c42b74068e2fa&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a997d2060d116c6cafbe787ec40bc9d78",
            "date": "2023-08-04",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "SynAct_Pharma_Q2_2023_Delarsrapport.pdf",
            "text_chars": 79425,
            "sha256": "f701b6dbdd4b13f3b5dc1caa01bfe0b81692fa88b8e68849f05ab2bc51a70c1b",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 79425
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-05-05",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "SynAct Pharma publicerar delårsrapport Q1 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b5d5fd93f70f6245f363ac48eb576df2c&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a567fdc9793be18c6b909ff87e1934bf6",
            "date": "2023-05-05",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "SynAct_Pharma_Q1_2023_Delarsrapport.pdf",
            "text_chars": 82787,
            "sha256": "57add4595e5fa405563d3c5e30f444197bdef62aeb4b8ba1fc6cd3f6f6e78407",
            "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 82787
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 16,
  "nasdaq_report_count": 16,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "SynAct Pharma AB",
    "identity": {
      "issuer": "SynAct Pharma AB",
      "lei": "549300RRYIEFEQ72N546",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 19,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "SynAct Pharma AB",
      "query": "SynAct Pharma AB",
      "candidate_count": 347
    },
    "period": {
      "from": "2024-08-07",
      "to": "2026-08-07",
      "years": 2
    },
    "generated_at": "2026-08-07T08:04:19Z",
    "insider": {
      "transactions": 20,
      "all_export_rows": 20,
      "acquisitions": 17,
      "disposals": 0,
      "other": 3,
      "acquisition_value_sek": 1828124.57,
      "disposal_value_sek": 0,
      "characters": {
        "Förvärv": 17,
        "Teckning": 3
      }
    },
    "short_selling": {
      "aggregate_percent": 2.07,
      "current_public_positions": 1,
      "historical_changes": 10,
      "current_position_sum_over_0_5": 0.79
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [
    "MFN fallback: resolved_no_reports"
  ],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "",
      "instrument_id": "TX4479212",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/synact?id=TX4479212"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "SynAct Pharma",
      "expected_name": "SynAct Pharma AB",
      "match_score": 100.0,
      "slug": "synact-pharma",
      "url": "https://mfn.se/all/a/synact-pharma",
      "metadata": {
        "country": "Sverige",
        "list": "Small Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Bioteknik",
        "website": "https://synactpharma.com/en/"
      },
      "ticker_candidates": [],
      "attempts": [
        {
          "slug": "synact-pharma-ab",
          "url": "https://mfn.se/all/a/synact-pharma-ab",
          "status": "identity_mismatch",
          "title": "",
          "score": 0.0
        }
      ]
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX4479212",
      "asset_class": "SHARES",
      "isin": "SE0008241491",
      "symbol": "SYNACT",
      "company": "SynAct Pharma",
      "market": null,
      "last_sale_price": "SEK 19.40",
      "time_as_of": "2026-08-06"
    },
    "finansinspektionen": {
      "issuer": "SynAct Pharma AB",
      "lei": "549300RRYIEFEQ72N546",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 19,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "SynAct Pharma AB",
      "query": "SynAct Pharma AB",
      "candidate_count": 347
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aef628bb051762f152807cda4a5c133c9",
      "date": "2026-05-27",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "SynAct_Pharma_Q1_2026_Delarsrapport.pdf",
      "text_chars": 89833,
      "sha256": "2e857f4d02c1d3a9483800a2d9b775729fff9fed9ee497f0973f7e87322e4b97",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 89833
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a459e70f487d42df785c6bb5c7faf489a",
      "date": "2026-04-15",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "SynAct_Pharma_AB_Arsredovisning_2025.pdf",
      "text_chars": 285170,
      "sha256": "990b1b3dd10a421ca68244074ce2aef48d441b54944c9d912f57803bcc3c6e91",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 179057
        },
        {
          "number": 2,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 106111
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aacfe3c91766da9d853ef2d782fed5c73",
      "date": "2026-02-18",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "SynAct_Pharma_Q4_2025_Delarsrapport.pdf",
      "text_chars": 90669,
      "sha256": "2b486bd51ce23ff281f5af5b5a73213867292be738267531cfc10cf2bf1f5de1",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 90669
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a9aa6754168c9d211bb79cf0bd9ea3c4e",
      "date": "2025-10-30",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "SynAct_Pharma_Q3_2025_Delarsrapport.pdf",
      "text_chars": 89961,
      "sha256": "334a266722ca6536cd1fa365a15bbb2bae489b22f558e145500792e705e29151",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 89961
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/abb85308bea260d076ba2c5c4f3950960",
      "date": "2025-08-20",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "SynAct_Pharma_Q2_2025_Delarsrapport.pdf",
      "text_chars": 85186,
      "sha256": "89acc586725d0dc585547f14d032093321e136369e5576f1b9bdb89a7d394660",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 85186
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/af03394fd18f44f9f7460b90bb573c281",
      "date": "2025-05-27",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "SynAct_Pharma_Q1_2025_Delarsrapport.pdf",
      "text_chars": 79745,
      "sha256": "f7fbf9bd26e12ccbb00005fd5f31a781c88390c9b399700675a1767f6b0fb6a2",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 79745
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a55291ac91810d4e6b483d2b5b3ff628e",
      "date": "2025-04-10",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "SynAct_Pharma_AB_Arsredovisning_2024.pdf",
      "text_chars": 280555,
      "sha256": "ce15cb2f11cde6b84bb7906187c0d60655e366a6916d188b4d0af5be1d3756ed",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 179972
        },
        {
          "number": 2,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 100581
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a7244d301ff63415f15fa946cdc137082",
      "date": "2025-02-18",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "SynAct_Pharma_Q4_2024_Delarsrapport.pdf",
      "text_chars": 77354,
      "sha256": "569b64ec4f7fc3bfe36417d573ad58a3909b9b3e69986e46c391cdd9eeb7a0fd",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 77354
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a624caea2485d1f24373c8eeaaa8a03be",
      "date": "2024-10-30",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "SynAct_Pharma_Q3_2024_Delarsrapport.pdf",
      "text_chars": 76160,
      "sha256": "7c8a711c3a4d3d8fa874537d61836642f5675e790a2499701709ecbc2640eba7",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 76160
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a9661055a47fa9fd0ca97f5c3119534ca",
      "date": "2024-08-20",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "SynAct_Pharma_Q2_2024_Delarsrapport.pdf",
      "text_chars": 69351,
      "sha256": "fa27f4242fb3a44034232792f64bf5f3afb3870e46a9daf45c4abca310838a00",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 69351
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aaf75ad2e30ba61a9470d9cf567dd8be5",
      "date": "2024-05-31",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "SynAct_Pharma_Q1_2024_Delarsrapport.pdf",
      "text_chars": 68803,
      "sha256": "913da495e5a30426e81fae77abcf35d33ce3b31cb011c79aacef0a522670f8f2",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 68803
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a1ec65c58dae6cb556634909826df1f8f",
      "date": "2024-03-26",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "SynAct_Pharma_AB_Arsredovisning_2023.pdf",
      "text_chars": 293672,
      "sha256": "9b266db204f6a3f046d1e162c09a076f94e134618085bb805c9248e197fe3732",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 179635
        },
        {
          "number": 2,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 114035
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a9cf323e4ab27f6b24e4e9b52cd7e85c4",
      "date": "2024-02-23",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "SynAct_Pharma_Q4_2023_Delarsrapport.pdf",
      "text_chars": 79563,
      "sha256": "2ab48236d6bcfe24afc35c6544ae3ec7a6b4d2926f084c562312dc86e60efd2c",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 79563
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a2addd2988ae7f74674ece98ee7708eff",
      "date": "2023-10-24",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "SynAct_Pharma_Q3_2023_Delarsrapport.pdf",
      "text_chars": 81241,
      "sha256": "55926ab9c1a78796f8773eced3b263b36a0e3f208958fc49f33948407ae5e0f9",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 81241
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a997d2060d116c6cafbe787ec40bc9d78",
      "date": "2023-08-04",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "SynAct_Pharma_Q2_2023_Delarsrapport.pdf",
      "text_chars": 79425,
      "sha256": "f701b6dbdd4b13f3b5dc1caa01bfe0b81692fa88b8e68849f05ab2bc51a70c1b",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 79425
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a567fdc9793be18c6b909ff87e1934bf6",
      "date": "2023-05-05",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "SynAct_Pharma_Q1_2023_Delarsrapport.pdf",
      "text_chars": 82787,
      "sha256": "57add4595e5fa405563d3c5e30f444197bdef62aeb4b8ba1fc6cd3f6f6e78407",
      "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 82787
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/synact-pharma",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 12805,
      "sha256": "fa65fb735ee584ba0ad662b2a7bd9e8ff2bbbe1b0ff48d51b16b25e406fe63ec",
      "url": "/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/synact-pharma-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 12805
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/synact-pharma-ab/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/synact-pharma-ab/market/history.json",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/synact-pharma-ab/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/synact-pharma-ab/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/market/instrument.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/synact-pharma-ab/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/synact-pharma-ab/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/synact-pharma-ab/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": false,
    "status": "inte hämtad",
    "captured_at": null,
    "view_count": 0,
    "url": "/company/synact-pharma-ab/morningstar"
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/synact-pharma-ab/finansinspektionen",
    "transaction_count": 20,
    "aggregate_short_percent": 2.07,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/synact-pharma-ab/llms.txt",
  "json_url": "/company/synact-pharma-ab/company.json",
  "document_index_url": "/company/synact-pharma-ab/documents.json",
  "absolute_url": "https://spela.port0.org/company/synact-pharma-ab"
}